Clozapine

Generic Name
Clozapine
Brand Names
Clozaril, Fazaclo, Versacloz
Drug Type
Small Molecule
Chemical Formula
C18H19ClN4
CAS Number
5786-21-0
Unique Ingredient Identifier
J60AR2IKIC
Background

Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramida...

Indication

Clozapine is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine should be used only in patients who have failed to respond adequately to standard antipsychotic treatment.
...

Associated Conditions
Suicidal Behaviour, Treatment Resistant Schizophrenia, Advanced dopaminomimetic psychosis
Associated Therapies
-
Clinical Trials
Related News

Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database

Conditions
Leukemia
Lymphoma
Interventions
Drug: Clozapine
First Posted Date
2019-08-30
Last Posted Date
2019-08-30
Lead Sponsor
University Hospital, Caen
Target Recruit Count
1000000
Registration Number
NCT04074213
Locations
🇫🇷

Caen University Hospital, Department of Pharmacology, Caen, Normandie, France

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

First Posted Date
2019-02-28
Last Posted Date
2020-03-23
Lead Sponsor
Augusta University
Target Recruit Count
100
Registration Number
NCT03857581
Locations
🇺🇸

Sandarsh Surya, Evans, Georgia, United States

Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia

First Posted Date
2019-01-17
Last Posted Date
2021-06-16
Lead Sponsor
All India Institute of Medical Sciences, Bhubaneswar
Target Recruit Count
60
Registration Number
NCT03807882
Locations
🇮🇳

Dept of Psychiatry, Aiims, Bhubaneswar, Bhubaneswar, Odisha, India

The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia

First Posted Date
2018-12-12
Last Posted Date
2022-01-11
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
154
Registration Number
NCT03772951
Locations
🇨🇳

Huangpu District Mental Health Center, Shanghai, Shanghai, China

Therapeutic Drug Monitoring for Individualized Clozapine Therapy

Conditions
Schizophrenia
First Posted Date
2018-05-14
Last Posted Date
2019-09-24
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
100
Registration Number
NCT03523741
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
Bipolar Disorder
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study

Conditions
Schizophrenia
Interventions
Drug: Clozapine
First Posted Date
2016-03-22
Last Posted Date
2022-06-03
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
108
Registration Number
NCT02714894
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Switching Antipsychotics: Abrupt Discontinuation Versus Overlap

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: Clozapine
First Posted Date
2015-12-28
Last Posted Date
2024-08-21
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
33
Registration Number
NCT02640300
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia

Phase 4
Recruiting
Conditions
Schizoaffective Disorder
Schizophrenia
Interventions
Drug: Clozapine
First Posted Date
2015-12-24
Last Posted Date
2023-09-07
Lead Sponsor
Centre for Addiction and Mental Health
Target Recruit Count
30
Registration Number
NCT02639702
Locations
🇨🇦

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Procedure: Blood sampling
Drug: Clozapine
First Posted Date
2015-12-09
Last Posted Date
2016-02-25
Lead Sponsor
Anders Fink-Jensen, MD, DMSci
Target Recruit Count
48
Registration Number
NCT02625103
Locations
🇩🇰

Psychiatric Centre Rigshospitalet, Copenhagen, København Ø, Denmark

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy